CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Guanfacine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04742673
NCT04742673Phase 2Completed
CompareCT.gov

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

Vanderbilt University Medical Center·interventional·Posted Feb 8, 2021·Updated Feb 19, 2026

In Brief

A Phase 2 clinical trial evaluating Guanfacine and Placebo for Critical Illness and 2 related conditions. Completed, enrolled 46 participants across 1 site.

Detailed Summary

This proof-of-concept study examines whether the acute brain dysfunction that occurs in critically ill patients is improved by administration of intravenous guanfacine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCritical Illness, Delirium, Cognitive Impairment
CountriesUnited States
CollaboratorsMassachusetts General Hospital, National Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 8, 2021
Enrollment StartMay 4, 2021
Primary CompletionMar 30, 2024
Study CompletionNov 30, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.4 years ago

Interventions

Guanfacinedrug

Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.

Placebodrug

Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.